Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Nov 24, 2022 1:47pm
200 Views
Post# 35125727

RE:RE:RE:RE:Momentum forward

RE:RE:RE:RE:Momentum forwardThe barking dogs are a team of bashers. Posting under various handles, under a few chat boards like SH.
I have yet to figure out their motivation?
Shorting, or trying to buyin lower, or part of a larger scheme.
Few realize that once MBc phase 3 enrolment starts, the China partner is entitled to about $18million in warrants. Price being 120% of the trailing SP average.
What better motivation to keep the price down.
Any investor holding Onc(y) shares, who goes on a public forum & bashes the company, Is demonstrating total irrational behaviour?
if one thinks the company & future is anything less than better than it is right now. Then sell & move on.
I am underwater with my shares. However, at this point in time & for quite some time...
I have seen Onc make considerable progress.
That being Most recently the Pancreatic cancer results alongside Roche.
im looking forward , as are the covering analysts to see a business development/ partnership ASAP
So, the Nas driven shorters, barking dogs have the day off.
i dont post every day. I do read every day.
intersting, ALL of the bashers only post when the market is open.
yet, they claim to hold shares & attest their doom & gloom words will have no effects on market.
anyhow.
nas is closed today & early tomorrow.
leaving little time before the Nov 6/7 SanAntonio breast cancer ONC abstracts.
Broader longer view: Onc needs a partner, they know it, the anakysts know it & the potential partners know.
that announcement will flow out of the data reveals upcoming.
Yes, we have heard this many times before, hence the struggle with SP.
repeating myself. After aware-1 & bracelet, there are no more road blocks.
Do or die....Q1 2023.
all of the data so far looks positive.

<< Previous
Bullboard Posts
Next >>